logo
These Shoes Made A European Vacation Comfy Despite Plantar Fasciitis

These Shoes Made A European Vacation Comfy Despite Plantar Fasciitis

Forbes6 days ago
Young Woman At Famous Fiordo Di Furore Bridge,Positano,Amalfi Coast,Italy getty
A few months ago, I couldn't walk across my kitchen without wincing in pain. Plantar fasciitis—the inflammation of the tissue that runs across the bottom of your foot—had taken hold for the first time in my life, and it felt like stepping on a hot spike every time I got up from a chair or climbed out of bed.
As someone who travels constantly and often racks up 12,000+ steps a day just getting from one city landmark to another, the timing couldn't have been worse. My upcoming four-week European trip through nine countries loomed on the calendar, and I wasn't sure how I was going to manage a single city block, let alone miles of cobblestone alleyways.
I tried everything: stretching, rolling, icing, wearing recovery slides, a brace worn while sleeping, visits to my chiropractor, and rest. Nothing provided real relief.
Then someone suggested I try the brand Hoka.
When I complained about my plantar fasciitis on Facebook, a handful of friends mentioned Hoka for their pillowy soles and performance-minded support. I wasn't hopeful—footwear 'miracles' are usually overhyped—but I was desperate enough to investigate.
I visited a specialty running store and worked with a staffer to try on several models. The difference in feel was immediate: Hokas are plush. One model, the Hoka Bondi 9, stood out from the rest. It had the highest level of cushioning in the Hoka lineup and a wide, stable base that felt noticeably better under my aching heel than anything I'd worn before. They weren't the sleekest or sexiest travel shoe, but at that point, I cared more about function than fashion.
'Hokas are very good shoes for plantar fasciitis because they provide cushioning with their thick shock-absorbing midsoles,' confirms Dr. Bobby Pourziaee, 'The High Heel Doctor' and board-certified foot and ankle surgeon. 'Also they have a low heel drop and a wide base which reduces and supports the plantar fascia insertion.'
The $190 price tag made me wince almost as much as my heel pain, but I walked out with my first pair—and brought them straight to Europe with no break-in period. Testing Hoka on Cobblestones and Long Days
Over the past two weeks, I have worn my Bondis nonstop. I have walked through cities like Dubrovnik, Istanbul and Athens. I trudged up ancient stairs, wandered through historic towns, and strolled coastal promenades. I averaged between 10,000 and 16,000 steps a day—often on uneven pavement and steep hills.
And for the first time in months, I wasn't in pain.
Not at the end of the day. Not when I woke up the next morning. Not even after hours of walking with no breaks.
I had to keep reminding myself that I was the same person who, just weeks earlier, couldn't make it through the grocery store without limping. Why Hoka Bondi Helps Plantar Fasciitis, According to a Podiatrist
There's a reason so many people rely on Hoka shoes for foot pain.
While I can only speak to my personal experience, the Bondis are known for offering several features that align with plantar fasciitis relief: Maximal cushioning : That signature Hoka marshmallow midsole absorbs shock and reduces the impact on your heel and arch—key areas affected by plantar fasciitis.
: That signature Hoka marshmallow midsole absorbs shock and reduces the impact on your heel and arch—key areas affected by plantar fasciitis. Rocker sole : The curved sole helps promote a smoother heel-to-toe transition, reducing strain on the plantar fascia.
: The curved sole helps promote a smoother heel-to-toe transition, reducing strain on the plantar fascia. Wide, stable platform: Bondis are built to be forgiving on joints while offering solid arch support—an important factor when you're on your feet for hours at a time.
'I believe what really sets them apart is that the materials used to make the shoe are high in quality which makes the shoes last a long time,' says Pourziaee. 'The supportive features of the shoes will continue to give reprieve even after your symptoms subside.'
While Hokas aren't the solution for everyone, they seem to be a game-changer for a growing number of people dealing with heel pain or inflammation-related foot conditions.
'I had a patient come with me for heel pain for two months and brought in five different pairs of shoes that she had bought,' says Pourziaee. 'None of it gave relief. After examining her and reviewing her X-rays I recommended the Bondi and had her do a rigorous stretching program. The pain was gone after three weeks.' Would I Recommend Hoka For Plantar Fasciitis?
Without hesitation.
I've worn many so-called 'comfort' shoes over the years and none have given me the consistent, all-day comfort that the Hokas have. And I'm not alone—once I started talking about them, other travelers began sharing their own plantar fasciitis success stories with the brand. And I noticed tons of people on my various tours and cruise excursions wearing the brand, too.
That said, they're not perfect for every situation. They're bulkier than a standard walking shoe (I wear them on the plane, so I don't have to pack them, but this also comes in handy walking through airports in comfort) and definitely more utilitarian than stylish. But when you're facing the very real possibility of canceling travel plans or missing out on experiences because of foot pain, priorities shift fast. A New Travel Essential for Plantar Fasciitis
I still stretch after long days on my feet, but I no longer dread walking. The Hoka Bondi gave me my mobility back—and, in a very real way, saved my trip.
As soon as I get home, I'm buying a second pair, because when your feet feel good, everything else about travel becomes easier, lighter, more joyful.
For me, the proof of plantar fasciitis relief is in the steps—over 150,000 of them over the last two weeks (and two more weeks to go in Europe), pain-free.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

European Commission Approves CAR-T Therapy With Lentiviral Vectors Manufactured by AGC Biologics
European Commission Approves CAR-T Therapy With Lentiviral Vectors Manufactured by AGC Biologics

Yahoo

time21 hours ago

  • Yahoo

European Commission Approves CAR-T Therapy With Lentiviral Vectors Manufactured by AGC Biologics

The Friendly CDMO Expert's Milan Cell and Gene Center of Excellence Achieves 10th Major Regulatory Product Approval MILAN, July 31, 2025--(BUSINESS WIRE)--Following news on July 21 that the European Commission has granted marketing authorization for AUCATZYL® (obecabtagene autoleucel – obe-cel), AGC Biologics' Milan site achieved its 10th product approval from the European Medicines Agency or the U.S. Food and Drug Administration. Developed by Autolus Therapeutics, AUCATZYL® is now approved to treat adult patients (age 26 and older) in 27 European Union member states with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL). This follows the therapy's prior authorizations from the FDA in November 2024 and the U.K. Medicines and Healthcare products Regulatory Agency in April 2025. This latest step further solidifies AGC Biologics' Milan Cell and Gene Center of Excellence's reputation as a global leader in the field, built on a 30-year track record of quality, reliability, and regulatory success. "This European approval for Autolus is a milestone we are thrilled to be part of. Our goal is to be the industry's safe harbor: a trusted, friendly expert CDMO that de-risks the complex path to commercialization," said Alberto Santagostino, CEO and President, AGC Biologics. "By ensuring a reliable supply of their vital lentiviral vector, we empower our partners to focus on patients. Congratulations to the entire Autolus team." The partnership between Autolus and AGC Biologics Milan began in 2020, with the CDMO tasked to develop, manufacture, and supply the viral vectors for Autolus' obe-cel CAR-T product candidate. "From the start of our partnership in 2020, through the FDA approval and now this European authorization, our collaboration with Autolus has been a model of true partnership," said Luca Alberici, General Manager, AGC Biologics Milan. "The team's sustained dedication and technical excellence is a direct result of our ability to work seamlessly with the Autolus team to meet the demands of commercial-scale manufacturing for a global market." With its 30-year track record and 10 product approvals by the EMA and FDA, the AGC Biologics Milan site is a global leader with deep expertise in complex cell and gene therapy projects. The team has guided numerous products to commercial stages, manufactured hundreds of batches for clinical supply, and consistently met the highest global regulatory guidelines, quality performance metrics, and the unique complexities of technology transfers and manufacturing scale-up. To learn more about AGC Biologics' global cell therapy services, visit and for more on the CDMO's viral vector offerings, visit About AGC Biologics AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, to provide friendly and expert services. We provide world-class development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with locations in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba and Yokohama, Japan. We currently employ more than 2,600 Team Members worldwide. AGC Biologics is a part of AGC Inc.'s Life Science Business. The Life Science Business runs 10+ facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. To learn more, visit AUCATZYL® (obecabtagene autoleucel – obe-cel) is a registered trademark of Autolus Therapeutics. View source version on Contacts AGC Inc. corporate contact: info-pr@ AGC Biologics media contact: ksills@ Sign in to access your portfolio

Risankizumab Maintains Long-Term Effectiveness in Psoriasis
Risankizumab Maintains Long-Term Effectiveness in Psoriasis

Medscape

timea day ago

  • Medscape

Risankizumab Maintains Long-Term Effectiveness in Psoriasis

TOPLINE: Risankizumab was well tolerated and demonstrated sustained effectiveness and drug survival in patients with moderate-to-severe psoriasis over a period of 4 years. Obesity, difficult-to-treat sites, and prior biologic use delayed the response, whereas bio-naive patients had faster first-year outcomes. METHODOLOGY: Researchers conducted an observational retrospective study of patients with moderate-to-severe psoriasis, with or without psoriatic arthritis, at the Turin University Hospital between 2020 and 2024. A total of 545 adult participants (mean age at psoriasis onset, 33.3 years; 60.1% men) received risankizumab 150 mg at weeks 0 and 4 and then every 12 weeks subsequently. Study outcomes were the achievement of Psoriasis Area and Severity Index (PASI) 100 and PASI 90 at various timepoints between weeks 16 and 208. Drug survival, defined as the time from initiation to discontinuation, was evaluated alongside predictors of response to risankizumab including obesity, bio-naive status, and difficult-to-treat sites. TAKEAWAY: The mean PASI score decreased significantly from 14 at baseline to 0.4 at week 208. PASI 100 responses increased from 33% at week 16 to 74% at week 208, and PASI 90 responses increased from 47% to 85% over the same period. Bio-naive patients achieved PASI 100 more often than bio-experienced patients at week 16 (38% vs 27%; P = .025), week 28 (63% vs 44%; P < .001), and week 52 (73% vs 57%; P = .002); similar trends were seen for PASI 90. Similarly, patients without obesity were significantly more likely than those with obesity to achieve PASI 100 (66% vs 55%; P = .029) and PASI 90 (78% vs 63%; P = .012) at week 52. Drug survival was notably high at 87.2% for the observed cases after week 208. The presence of a difficult-to-treat site significantly reduced the risk for interruption (hazard ratio, 0.15; P < .001). Overall, 11.6% of patients discontinued the treatment, with the leading cause being secondary failure (38.1%), and adverse events prompted discontinuation in 13 patients. IN PRACTICE: "Risankizumab showed excellent effectiveness, safety, and DS [drug survival] over 4 years of treatment," the authors wrote. "Obesity and involvement of a difficult-to-treat area can lower the initial response, even if they did not affect treatment interruption," they concluded, observing that "bio-naïve patients benefit from a faster response during the first year of treatment." SOURCE: This study was led by Luca Mastorino, Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy. It was published online on July 23, 2025, in Clinical and Experimental Dermatology. LIMITATIONS: The analysis of observed cases and those lost to follow-up weakened the 4-year survival estimate, showcasing an inherent limitation of real-world studies. Additionally, this study could not differentiate effectiveness on the basis of different difficult-to-treat sites. DISCLOSURES: This study did not receive any specific grant from any funding agency in the public, commercial, or not-for-profit sectors. The authors declared having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Jefferies Reaffirms ‘Buy' Rating on LivaNova PLC (LIVN) with $79 PT
Jefferies Reaffirms ‘Buy' Rating on LivaNova PLC (LIVN) with $79 PT

Yahoo

time2 days ago

  • Yahoo

Jefferies Reaffirms ‘Buy' Rating on LivaNova PLC (LIVN) with $79 PT

Offering strong upside potential, LivaNova PLC (NASDAQ:LIVN) earns a spot on our list of the . A closeup shot of a laboratory technician handling a medical device used for fertility treatments. On June 5, 2025, LivaNova PLC (NASDAQ:LIVN) reported the completion of its landmark CORE-VNS study. More than 800 real-world patients with drug-resistant epilepsy were tracked under this study. The results were positive. Significant and lasting seizure reductions were noted, confirming VNS Therapy's effectiveness in both children and adults. In some cases, a 100% reduction was noted. In response to the positive results, Jefferies reaffirmed its 'Buy' rating the following day, with a $79 price target. The analyst attributed it to strong product cycles, including upgrades to the company's Essenz platform and growing oxygenator market share. Previously, in May, Wolfe Research also upgraded the stock to 'Outperform', highlighting the improved legal clarity in Italy and high growth potential in its depression and sleep apnea treatment pipelines. Through its Cardiopulmonary and Neuromodulation segments, LivaNova PLC (NASDAQ:LIVN) develops products and therapies for neurological and cardiac patients worldwide. It remains on our list of the most undervalued stocks. While we acknowledge the potential of LIVN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 11 Most Undervalued Cloud Stocks Under $10 According to Hedge Funds and 11 Best Mineral Stocks to Buy According to Hedge Funds. Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store